UNSPSC 51312605: Mifentidine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2F70KF5S0K. European Medicines Agency schedules Mifentidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08955MIG. Mifentidine generally arises in the molecular formula C13H16N4.

UNSPSC 51312605 Mifentidine is a Commodity code covering pharmaceutical products purchased by state and local health agencies, though recent state and local solicitations tagged to this code show divergent scope — they include naloxone procurement, generic multi-source pharmaceuticals and over-the-counter products, and pharmacy program capabilities rather than mifentidine specifically. State and local buyers under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida has posted a competitive bid (IFB) for naloxone and drug deactivation systems, while the Texas Health and Human Services Commission issued a market-intelligence RFI on therapeutic pharmacy initiatives, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic pharmaceuticals and OTC products. The diversity of issuing bodies and procurement mechanisms reflects the range of health-focused purchasing across state agencies, counties, and cooperative vehicles.

Activity is concentrated in Florida, Texas, and Minnesota. Seminole County's naloxone solicitation (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery to the Seminole County Community Health Building in Sanford. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) focused on vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager arrangements. MMCAP's RFP (S1070000015802, due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026, and requiring certification under current Good Manufacturing Practices and the Drug Supply Chain Security Act. Vendors pursuing this code should note that recent opportunities span community health product acquisition, state pharmacy program strategy, and cooperative pharmaceutical distribution — a scope broader than mifentidine alone.